Cited by

• Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice.

  Ellis MH, Tadmor T, Yekutiel N, Chodick G, Levy M, Sharf G, Ben Zvi N, Leef R, Feine O, Shavit O. Ellis MH, et al. J Clin Med. 2024 Jun 10;13(12):3390. doi: 10.3390/jcm13123390. J Clin Med. 2024. PMID: 38929918 Free PMC article.
• Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.

  Kuykendall AT. Kuykendall AT. Ann Hematol. 2023 May;102(5):985-993. doi: 10.1007/s00277-023-05172-y. Epub 2023 Mar 21. Ann Hematol. 2023. PMID: 36944847 Free PMC article. Review.
• Delayed diagnosis of polycythaemia vera in an adult female with non-cirrhotic portal hypertension.

  Tachi K, Ekem V, Dei-Adomakoh Y. Tachi K, et al. Ghana Med J. 2022 Mar;56(1):38-41. doi: 10.4314/gmj.v56i1.6. Ghana Med J. 2022. PMID: 35919777 Free PMC article.
• SOHO State-of-the-Art Update and Next Questions: MPN.

  Bose P, Gotlib J, Harrison CN, Verstovsek S. Bose P, et al. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):1-12. doi: 10.1016/j.clml.2017.11.008. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29277359 Free PMC article. Review.
• Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

  Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Vannucchi AM, et al. N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002. N Engl J Med. 2015. PMID: 25629741 Free PMC article. Clinical Trial.